Takeda Pharmaceutical
(NYSE) TAK
Takeda Pharmaceutical Financials at a Glance
Market Cap
$53.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
¥4.55T
Net Income (TTM)
¥193.19B
EPS (TTM)
-$0.29
P/E Ratio
-60.09
Dividend
$0.63
Beta (Volatility)
0.32 (Low)
Dividend
$0.63
Beta (Volatility)
0.32 (Low)
Price
$16.99
Volume
31,629
Open
$16.91
Price
$16.99
Volume
31,629
Open
$16.91
Previous Close
$16.89
Daily Range
$16.89 - $17.11
52-Week Range
$12.99 - $18.90
Estimated Earnings Date
Jul 30, 2026
Dividend
$0.63
Beta (Volatility)
0.32 (Low)
Price
$16.99
Volume
31,629
Open
$16.91
Previous Close
$16.89
Daily Range
$16.89 - $17.11
52-Week Range
$12.99 - $18.90
Estimated Earnings Date
Jul 30, 2026
TAK News
TAK: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Takeda Pharmaceutical
Industry
Pharmaceuticals
Sector
Health CareEmployees
47,029
CEO
Christophe Weber, PhD
Website
www.takeda.comHeadquarters
Tokyo, 103-8668, JP
TAK Financials
Key Financial Metrics (TTM)
Gross Margin
58.76%
Operating Margin
10.54%
Net Income Margin
4.26%
Return on Equity
2.61%
Return on Capital
4.51%
Return on Assets
1.24%
Earnings Yield
-1.66%
Dividend Yield
3.73%
Payout Ratio
1.63%
Stock Overview
Market Cap
$53.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
3.16B
Volume
31.63K
Avg. Volume
3.03M
Financials (TTM)
Gross Profit
¥2.66T
Operating Income
¥495.17B
EBITDA
¥1.37T
Operating Cash Flow
¥986.56B
Capital Expenditure
-¥395.93B
Free Cash Flow
¥590.62B
Cash & ST Invst.
¥597.63B
Total Debt
¥4.90T
Takeda Pharmaceutical Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
¥1.11T
+5.8%
Gross Profit
¥543.81B
-19.0%
Gross Margin
48.79%
N/A
Market Cap
$53.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$1.08M
N/A
Employees
49,281
N/A
Net Income
-¥24.77B
+76.0%
EBITDA
¥157.89B
-12.9%
Quarterly Fundamentals
Total Cash
¥597.63B
+47.3%
Total Debt
¥4.90T
+8.6%
Accounts Receivable
¥880.15B
+21.4%
Inventory
¥1.40T
+15.2%
Long Term Debt
¥4.39T
+10.6%
Short Term Debt
¥514.38B
-6.3%
Return on Assets
1.24%
N/A
Return on Invested Capital
3.65%
N/A
Free Cash Flow
-¥26.01B
-115.0%
Operating Cash Flow
¥19.66B
-91.2%